[5-(Benzyloxy)-1H-indol-1-yl]acetic acid, an aldose reductase inhibitor and PPARγ ligand.

  • Marta Soltesova Prnova Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Bratislava, Slovakia.;
  • Magdalena Majekova Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Bratislava, Slovakia.;
  • Ivana Milackova Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Bratislava, Slovakia.;
  • Beatriz Díez-Dacal Department of Chemical and Physical Biology, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.;
  • Dolores Pérez-Sala Department of Chemical and Physical Biology, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.;
  • Muserref Seyma Ceyhan Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.;
  • Sreeparna Banerjee Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.;
  • Milan Stefek Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Bratislava, Slovakia.;

Abstract

Based on overlapping structural requirements for both efficient aldose reductase inhibitors and PPAR ligands, [5-(benzyloxy)-1H-indol-1-yl]acetic acid (compound 1) was assessed for inhibition of aldose reductase and ability to interfere with PPARγ. Aldose reductase inhibition by 1 was characterized by IC50 in submicromolar and low micromolar range, for rat and human enzyme, respectively. Selectivity in relation to the closely related rat kidney aldehyde reductase was characterized by approx. factor 50. At organ level in isolated rat lenses, compound 1 significantly inhibited accumulation of sorbitol in a concentration-dependent manner. To identify crucial interactions within the enzyme binding site, molecular docking simulations were performed. Based on luciferase reporter assays, compound 1 was found to act as a ligand for PPARγ, yet with rather low activity. On balance, compound 1 is suggested as a promising lead-like scaffold for agents with the potential to interfere with multiple targets in diabetes.
Published
2015-09-08
Section
Articles